Medicine Press release



Biogen and Eisai Announce ADUHELM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021
Jul 27, 2021 08:00 JST
Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen, as part of its Alzheimer's disease (AD) research portfolio, will contribute four virtual posters that showcase data from its clinical trials with ADUHELMTM (aducanumab-avwa) injection 100 mg/mL solution at the AAIC.
More info..


Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
Jul 23, 2021 08:17 JST
Study Results Demonstrated Statistically Significant Improvements in Overall Survival, Progression-Free Survival and Overall Response Rate, Helping to Address a Significant Unmet Need in Advanced Endometrial Carcinoma.
More info..


Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
Jul 23, 2021 08:17 JST
Study Results Demonstrated Statistically Significant Improvements in Overall Survival, Progression-Free Survival and Overall Response Rate, Helping to Address a Significant Unmet Need in Advanced Endometrial Carcinoma.
More info..


Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021
Jul 21, 2021 09:34 JST
Eisai Co., Ltd. announced today that the company will conduct a total of 11 presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401) for which the U.S. Food and Drug Administration has granted Breakthrough Therapy designation, at the Alzheimer's Association International Conference (AAIC).
More info..


Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand
Jul 19, 2021 08:03 JST
Eisai Co., Ltd. announced that its Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofice (generic name: elobixibat hydrate) in Thailand.
More info..


NEC's artificial intelligence (AI) supports doctors to determine if colorectal lesions are potentially neoplastic
Jul 14, 2021 17:15 JST
NEC Corporation announced today the development of an AI technology for supporting doctors in determining if colorectal lesions are neoplastic or non-neoplastic.
More info..


Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong
Jul 01, 2021 10:43 JST
Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
More info..


Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401)
Jun 24, 2021 11:00 JST
Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of Alzheimer's disease (AD).
More info..


Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma
Jun 23, 2021 14:20 JST
Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing approval for the EZH2 inhibitor "Tazverik Tablets 200 mg" (tazemetostat hydrobromide) in Japan with the indication of relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable).
More info..


Fujitsu Japan Embarks on Joint Research for COVID-19 Therapies Using World's Fastest Supercomputer with Researchers of RCAST, The University of Tokyo
Jun 22, 2021 09:30 JST
Fujitsu Japan Limited today announced that it will initiate a new research project with a research team led by Takefumi Yamashita, Project Associate Professor of Research Center for Advanced Science and Technology (RCAST) , the University of Tokyo utilizing the world's fastest supercomputer, Fugaku, which was jointly developed by RIKEN and Fujitsu.
More info..